Novartis study shows benefits of Cosentyx in psoriatic arthritis

Novartis has announced the findings of a new clinical trial that offers further evidence of the benefits Cosentyx can provide to people with psoriatic arthritis.

Data from the phase III FUTURE 5 study showed that Cosentyx can reduce the signs and symptoms of psoriatic arthritis, while also significantly inhibiting the progression of joint structural damage, compared to placebo after 24 weeks of treatment.

FUTURE 5 represents the largest randomised controlled trial of a biologic therapy conducted with psoriatic arthritis patients to date, with nearly 1,000 participants studied. Efficacy across all endpoints was greater in patients who had not been previously treated with anti-TNF therapies.

This could mark a significant step forward in the treatment of this painful and progressively debilitating inflammatory disease, with up to 40 percent of psoriatic arthritis patients suffering from joint damage and permanent physical deformity.

Vas Narasimhan, global head of drug development and chief medical officer at Novartis, said: "The results are encouraging, as they provide important information about the ability of Cosentyx to address key areas of concern for physicians when managing the symptoms and the underlying progression of joint structural damage of psoriatic arthritis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.